IQ-AI Limited IB Awarded $2.57m grant (4190O)
June 01 2020 - 2:00AM
UK Regulatory
TIDMIQAI
RNS Number : 4190O
IQ-AI Limited
01 June 2020
IQ-AI Ltd
("IQ-AI" or the "Company")
Imaging Biometrics in Collaboration With Three Top Imaging
Centers
Awarded $2.57m NIH Grant
Imaging Biometrics(TM), LLC (IB), a subsidiary of IQ-AI Limited
(LON:IQAI), in collaboration with the Barrow Neurological Institute
(BNI), the Mayo Clinic (AZ), and the Medical College of Wisconsin
(MCW), has received a $2.57 million, five-year grant award from the
National Institutes of Health(NIH) - National Cancer Institute
(NCI). Funding for this effort begins 1(st) July with the primary
purpose of optimising and validating multi-vendor quantitative
perfusion tools for the prediction of brain tumor response to
therapy on a patient-specific basis.
Principal Investigator, Chad Quarles, PhD, Professor and Chair
of the Division of Neuroimaging Research at BNI (Phoenix, AZ), will
lead this multi-institutional effort to provide brain tumor
physicians with a novel MRI method that provides several different
measures of tumor biology using just one MRI technique, called SAGE
(spin and gradient echo [MRI]). The additional biological
information will help doctors determine how best to combine
therapies, and will complement IB's current methods of monitoring
treatment response. This NIH-funded effort also includes a plan to
harmonise the way SAGE data is collected and analysed across sites
and MRI vendors. IB's experience in providing vendor-neutral and
standardised software is key to this effort, and IB's participation
in this effort will further expand its footprint as the recognised
leader in brain cancer imaging and assessing treatment
response.
Michael Schmainda, CEO of IB, added, "Since our inception in
2007, NIH grant funding has helped fuel our business by enabling us
to accelerate the development and translation of novel imaging
technologies into practical products. Not only does this grant
provide a financial boost for IB, it further strengthens our
relationships with recognized leaders in MR imaging."
The Directors of the Company accept responsibility for the
contents of this announcement.
-ENDS-
For further information, please contact:
IQ-AI Limited
Trevor Brown/Vinod Kaushal/Qu Li
Tel: 020 7469 0930
----------------------------------------------------------
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
----------------------------------------------------------
ABOUT Imaging Biometrics(TM) , LLC
Imaging Biometrics, a subsidiary of IQ-AI Limited (LON:IQAI),
develops and provides visualisation and analytical solutions that
enable clinicians to better diagnose and treat disease with greater
confidence. Through close collaboration with top researchers and
clinicians, sophisticated advancements are translated into
platform-independent and automated software plug-ins which can
extend the base functionality of workstations, imaging systems,
PACS, or medical viewers. By design, IB's advanced visualisation
software seamlessly integrates into routine workflows. For more
information about Imaging Biometrics, visit the company's website
at www.imagingbiometrics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
STRBSGDUUBDDGGC
(END) Dow Jones Newswires
June 01, 2020 02:00 ET (06:00 GMT)
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Jul 2024 to Aug 2024
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Aug 2023 to Aug 2024